Advertisement

Topics

AACR 2018: Updated OS data for olaparib in gBRCA-Mutated HER2 negative metastatic breast cancer

07:42 EDT 16 Apr 2018 | ecancermedicalscience

Data from the Phase III OlympiAD trial, showing the final overall survival (OS) results for olaparib in metastatic breast cancer was presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018. The trial...

Original Article: AACR 2018: Updated OS data for olaparib in gBRCA-Mutated HER2 negative metastatic breast cancer

NEXT ARTICLE

More From BioPortfolio on "AACR 2018: Updated OS data for olaparib in gBRCA-Mutated HER2 negative metastatic breast cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...